CN101072879B - 改良的腺病毒载体及其应用 - Google Patents

改良的腺病毒载体及其应用 Download PDF

Info

Publication number
CN101072879B
CN101072879B CN2005800351365A CN200580035136A CN101072879B CN 101072879 B CN101072879 B CN 101072879B CN 2005800351365 A CN2005800351365 A CN 2005800351365A CN 200580035136 A CN200580035136 A CN 200580035136A CN 101072879 B CN101072879 B CN 101072879B
Authority
CN
China
Prior art keywords
carrier
serotype
adenovirus
immunity
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800351365A
Other languages
English (en)
Chinese (zh)
Other versions
CN101072879A (zh
Inventor
曼佐·扬斯·埃姆科·海文加
丹·巴罗什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Beth Israel Deaconess Medical Center Inc
Original Assignee
Crucell Holand BV
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV, Beth Israel Deaconess Medical Center Inc filed Critical Crucell Holand BV
Priority claimed from PCT/EP2005/055183 external-priority patent/WO2006040330A2/en
Publication of CN101072879A publication Critical patent/CN101072879A/zh
Application granted granted Critical
Publication of CN101072879B publication Critical patent/CN101072879B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN2005800351365A 2004-10-13 2005-10-12 改良的腺病毒载体及其应用 Expired - Fee Related CN101072879B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US61846904P 2004-10-13 2004-10-13
US60/618,469 2004-10-13
EP04105005 2004-10-13
EP04105005.5 2004-10-13
US69772405P 2005-07-08 2005-07-08
US60/697,724 2005-07-08
PCT/EP2005/055183 WO2006040330A2 (en) 2004-10-13 2005-10-12 Improved adenoviral vectors and uses thereof

Publications (2)

Publication Number Publication Date
CN101072879A CN101072879A (zh) 2007-11-14
CN101072879B true CN101072879B (zh) 2011-05-11

Family

ID=34929696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800351365A Expired - Fee Related CN101072879B (zh) 2004-10-13 2005-10-12 改良的腺病毒载体及其应用

Country Status (6)

Country Link
JP (1) JP4843613B2 (pt)
CN (1) CN101072879B (pt)
AT (1) ATE492643T1 (pt)
DE (1) DE602005025512D1 (pt)
ES (1) ES2358523T3 (pt)
ZA (1) ZA200702792B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111108192A (zh) * 2017-07-05 2020-05-05 Nouscom股份公司 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
WO2011129468A1 (en) * 2010-04-14 2011-10-20 Mogam Biotechnology Research Institute Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
PL2655604T3 (pl) * 2010-12-14 2019-02-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom
CN102199616B (zh) * 2011-03-07 2013-04-24 首都医科大学附属北京佑安医院 Hiv-1表型耐药检测载体及其构建方法
US9629906B2 (en) * 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
CN105431169B (zh) * 2012-03-22 2019-04-02 扬森疫苗与预防公司 抗rsv疫苗
MX2018001182A (es) 2015-07-28 2018-04-20 Univ Pennsylvania Monocitos/macrofagos modificados que expresan receptores de antigeno quimerico y sus usos.
WO2018111767A1 (en) * 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN106868047B (zh) * 2017-03-07 2020-04-28 南方医科大学 一种重组腺病毒载体及其构建方法和用途
CN107267469B (zh) * 2017-08-22 2020-06-16 广州医科大学附属第一医院 纤毛蛋白嵌合型重组人b型腺病毒及其制备方法
CA3077630A1 (en) * 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
KR20200074987A (ko) * 2017-10-31 2020-06-25 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
WO2019195444A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
CN113227361A (zh) * 2018-11-21 2021-08-06 梅奥医学教育及研究基金会 腺病毒和使用腺病毒的方法
EP3927833A4 (en) * 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
JP2023529841A (ja) 2020-06-04 2023-07-12 カリスマ セラピューティクス インコーポレイテッド キメラ抗原受容体のための新規コンストラクト
CN114262692A (zh) * 2021-11-30 2022-04-01 华中科技大学同济医学院附属同济医院 一种携带tmvp1和hsv-tk的溶瘤腺病毒重组体，其构建方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
AU2002322285A1 (en) * 2001-06-22 2003-01-08 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Gall J, et al.Construction and characterization of hexon-chimericadenoviruses: specification of adenovirus serotype.Journal of Virology72 12.1998,72(12),第10260-10264页.
Gall J, et al.Construction and characterization of hexon-chimericadenoviruses: specification of adenovirus serotype.Journal of Virology72 12.1998,72(12),第10260-10264页. *
Sakurai F, et al.Efficient gene transfer into human CD34+ cells by anadenovirus type 35 vector.Gene Therapy10.2003,10第1041-1048页. *
Shayakhmetov DM, et al.The interaction between the fiber knob domain and thecellular attachment receptor determines the intracellular.Journal of Virology77 6.2003,77(6),第3712-3723页.
Shayakhmetov DM, et al.The interaction between the fiber knob domain and thecellular attachment receptor determines the intracellular.Journal of Virology77 6.2003,77(6),第3712-3723页. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111108192A (zh) * 2017-07-05 2020-05-05 Nouscom股份公司 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途
CN111108192B (zh) * 2017-07-05 2023-12-15 Nouscom股份公司 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途

Also Published As

Publication number Publication date
CN101072879A (zh) 2007-11-14
ATE492643T1 (de) 2011-01-15
JP4843613B2 (ja) 2011-12-21
DE602005025512D1 (de) 2011-02-03
ES2358523T3 (es) 2011-05-11
ZA200702792B (en) 2007-12-27
JP2009523007A (ja) 2009-06-18

Similar Documents

Publication Publication Date Title
CN101072879B (zh) 改良的腺病毒载体及其应用
CA2583843C (en) Improved adenoviral vectors and uses thereof
EP1998804B1 (en) Compositions comprising a recombinant adenovirus and an adjuvant
US8216834B2 (en) Chimpanzee adenovirus vaccine carriers
US8227243B2 (en) Settings for recombinant adenoviral-based vaccines
JP5175178B2 (ja) ワクチン組成物
AU2015238866A1 (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US7968286B2 (en) Settings for recombinant adenoviral-based vaccines
CA2518926A1 (en) Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
WO2004097016A1 (en) Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
CN104419717B (zh) 逃避预存免疫的重组腺病毒及其构建方法和用途
US20060165664A1 (en) Method of inducing an enhanced immune response against hiv
Iampietro Immunogenicity and Cross-reactivity of Human and Rhesus Adenoviral Vectors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110511

Termination date: 20171012

CF01 Termination of patent right due to non-payment of annual fee